17 results about "Azacitidine" patented technology

The invention relates to the field of anti-tumor drugs, and discloses an anti-diffuse large B-cell lymphoma pharmaceutical composition, a preparation method and application thereof, the composition comprises azacitidine and Sanilisoma, the composition can improve the accumulation amount of VDUP1 protein in a cell nucleus through the combination of the methylation effect of DNMT3b on VDUP1 protein and the inhibition of XPO1 activity by Sanilisoma, and the anti-diffuse large B-cell lymphoma pharmaceutical composition can be used for preparing anti-diffuse large B-cell lymphoma. The chemotherapy effect is remarkably improved, the sensitivity of the DLBCL to the Sanisole is remarkably improved, and particularly, the pharmaceutical composition has a remarkable curative effect on R / R DLBCL patients.

The invention discloses a combined treatment medicine for acute myelogenous leukemia. The combined treatment medicine is prepared from vinaclaria, azacitidine and aclarithromycin. The medicine is applied to preparation of an acute myelogenous leukemia cell proliferation inhibitor; the medicine is applied to preparation of an acute myelogenous leukemia cell apoptosis inducer. The three medicines are combined to achieve a synergistic effect: the three medicines have a synergistic anti-tumor effect instead of a simple superposition effect, and a new combined medication mechanism is a result obtained through laboratory research and an initial effect of clinical application. The subsequent consolidation treatment scheme may also be used for part of initially treated patients with acute myelogenous leukemia, which are not suitable for enhanced chemotherapy or intense intense treatment by using targeted drugs, and relapse / refractory patients with acute myelogenous leukemia, and a better treatment scheme can also bring new hope and dawn to more patients.

The present disclosure relates generally to pharmaceutical dosage forms comprising azacitidine and chidaridine.

The present invention provides a composition comprising a cytidine analog, in particular decitabine or azacitidine. In particular, the present invention provides a composition comprising a cytidine analog, in particular decitabine or azacitidine, which is useful for topical application. The present invention also provides the use of such compositions for medical conditions in the keratinizing and non-keratinizing epithelium / skin, such as the treatment of human papillomavirus (HPV)-related pre-cancerous conditions.

The application discloses application of DNA methyltransferase inhibitors in preparation of drugs for treating polycystic kidney disease. Preferably, the DNA methyltransferase inhibitor is decitabine or azacitidine, and the polycystic kidney disease is polycystic kidney disease caused or aggravated by mTOR activation. The application uses Tsc2 knockout mouse embryo fibroblasts MEF and Tsc2 kidney-specific knockout mice, finds that after treatment of the DNA methyltransferase inhibitor decitabine, cell proliferation is inhibited, polycystic kidney disease of the mice is relieved, and kidney function is partially recovered. The application provides a new and effective technical means for treatment of polycystic kidney disease.

The present disclosure relates to a CD47-SIRPα blocking agent of formula (I) stereoisomers thereof, and pharmaceutically acceptable salts, solvates, amides and esters of the compound of formula (I) and stereoisomer thereof and Azacitidine for use in combination with Azacitidine in a method of treating or delaying progression of a disease or a disorder mediated by CD47-SIRPα pathway in a human subject suffering from said disease, such as hematological cancer.

Methods of treating patients diagnosed with cancer harboring an IDH-1 mutation are provided, including the therapeutic administration of a certain inhibitor of a mutant IDH-1 as a single agent, or in combination with azacitidine (AZA).

The present invention provides a compound of Formula (I), or a salt thereof : (I) for use in the treatment or prophylaxis of a cancer, wherein the compound of Formula (I) is administered in combination with Azacitidine and Venetoclax wherein the three compounds are administered simultaneously, sequentially or separately.

The invention provides a light-triggered epigenetic reprogramming engineering microorganism with a CT (Computed Tomography) imaging function as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. The engineering microbial strain provided by the invention is prepared by coupling Mo1.33C nanosheets and azacitidine independently or jointly as active pharmaceutical ingredients and facultative anaerobic escherichia coli capable of realizing precise delivery of tumor sites as a carrier. An effective delivery platform of a DNMT1 inhibitor and / or iMxene is established, epigenetic immunity is activated, a way is laid for epigenetic regulation in solid tumor treatment, meanwhile, Mo1. 33C is a reagent for CT imaging and infrared imaging and can be used for multi-mode diagnosis and PTT and epigenetic treatment, and an integrated diagnosis and treatment nano platform is created.

The present disclosure relates to a CD47-SIRPα blocking agent of formula (I) stereoisomers thereof, and pharmaceutically acceptable salts, solvates, amides and esters of the compound of formula (I) and stereoisomer thereof and Azacitidine for use in combination with Azacitidine in a method of treating or delaying progression of a disease or a disorder mediated by CD47-SIRPα pathway in a human subject suffering from said disease, such as hematological cancer.

The presented invention relates to Azacitidine (compound of formula (1)) particles characterized by bimodal particle size distribution, process for preparation thereof and composition comprising them.

The present disclosure relates generally to pharmaceutical dosage forms comprising azacitidine and cedazuridine.

The present disclosure relates generally to pharmaceutical dosage forms comprising azacitidine and cedazuridine.

The invention belongs to the technical field of medicinal preparations of antiviral drugs, and particularly relates to freeze-dried powder containing azacitidine gold nano-liposomes, application and a process. The freeze-dried powder contains the following components in parts by weight: 10 parts of azacitidine gold nano-liposome and 20-36 parts of a protective agent, the azacitidine gold nano-liposome is prepared from the following raw materials in parts by weight: 5 to 10 parts of carboxylated-azacitidine, 10 to 20 parts of PEG (Polyethylene Glycol)-gold nanoparticles, 15 to 35 parts of hydrogenated soybean phospholipid, 2 to 7 parts of taraxasterol and 5 to 11 parts of distearoyl phosphatidyl ethanolamine-polyethylene glycol 2000. By optimizing the formula, the drug encapsulation efficiency and the drug loading capacity can be guaranteed at the same time, the finally prepared freeze-dried powder has high stability, and in rat experiments, the drug has a lasting effect and can effectively reduce the tumor volume and prolong the survival days.

The application relates to the field of medicine synthesis, in particular to a refining method of azacitidine. Crude azacitidine is added into a refining solvent to be stirred and dissolved, a crystallization solvent is added dropwise to be stirred, after crystals are separated out, temperature is reduced to be stirred to separate out crystals, and then filtration is carried out; the filter cake is washed with the crystallization solvent, and high-purity single crystal azacitidine is obtained; the refining solvents used in the application are low-toxicity solvents, the operation is simple and safe, and the problem of excessive residue is avoided; the crystallization solvents are low-boiling-point solvents, which are beneficial to recycling and utilization of the crystallization solvents and cost saving. Finally, single crystal products are obtained, the problem caused by different crystal types is avoided, the yield is improved, the operation is simplified, and the method is suitable for industrial production.

Methods of treating patients diagnosed with AML or MDS harboring mutant IDH-1 include detecting an IDH1 mutation and the therapeutic administration of an inhibitor of a mutant IDH-1 as a single agent, or in combination with azacitidine (AZA) or cytarabine.